We have acquired a stake in Single Use Support GmbH (SUS) within the framework of a capital increase. With our support, the technology company based in Kufstein, Austria, intends to further advance its international growth and expand its sales structures.
The Börsen-Zeitung reports about the newly issued SHS-Medtech-Index, which was jointly developed by Christian Koziol, Head of the Finance Department of the University of Tübingen, and SHS.
The Frankfurter Allgemeine Zeitung reports about the newly issued SHS-Medtech-Index, which was jointly developed by Christian Koziol, Head of the Finance Department of the University of Tübingen, and SHS.
Based on an innovative combination of materials, Betterguards has developed a platform technology that protects human joints and prevents ligament and tendon injuries.
The life science company supplies large pharmaceutical and biotech companies with customized antibodies for research purposes. For SHS, it is the first investment from its SHS V fund, which had its first closing in July 2018.
We have sold our shareholding in Tuttlingen-based Emerging Implant Technologies GmbH (EIT) to Johnson & Johnson Medical GmbH. In 2016 we have invested in the medtech company as lead investor.
The fifth generation of SHS funds is also focused on the life sciences and medical technology sector, and thus on the growing global healthcare market with innovative and strong Players.
With the acquisition of Innocath, Novo Klinik-Service is complementing its product portfolio in the field of airway management. The partnership will open up further growth opportunities and sales activities.
SHS partner Dr. André Zimmermann talks to the FAZ about SHS’ new medical technology fund
